AstraZeneca's Evusheld loses potency against new omicron subvariant, FDA warns

Monday, amid reports that the antibody combo is ineffective against the latest subvariant of omicron, BA.4.6, the FDA has updated (PDF) its fact sheet for Evusheld, saying it can increase the risk of COVID-19 infection for variants that the product does not neutralize.